Calzado M A, Bacher S, Schmitz M L. 2007. NF-κB inhibitors for the treatment of inflammatory diseases and cancer. Current Medicinal Chemistry, 14, 367-376. Camandola S, Mattson M P. 2007. NF-κB as a therapeutic target in neurodegenerative diseases. Expert Opinion on Therapeutic Targets, 11, 123-132. Choi J, Enis D R, Koh K P, Shiao S L, Pober J S. 2004. T lymphocyte-endothelial cell interactions. Annual Review of Immunology, 22, 683-689. Collins T, Read M A, Neish A S, Whitley M Z, Cordle S R, Donald R, Read M A, Hawiger J. 1993. Lipopolysaccharide induces phosphorylation of MAD3 and activation of c-Rel and related NF-κB proteins in human monocytic THP-1 cells. Journal of Biological Chemistry, 268, 11803- 11810. Feldmann M, Maini R N. 2001. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned. Annual Review of Immunology, 19, 163-196. Hindryckx P, de Vos M, Jacques P, Ferdinande L, Peeters H, Olievier K, Bogaert S, Brinkman B, Vandenabeele P, Elewaut D, et al. 2010. Hydroxylase inhibition abrogates TNF-α- induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD. The Journal of Immunology, 185, 6306-6316. Kaileh M, Sen R. 2010. Role of NF-κB in the anti-inflammatory effects of Tocotrienols. Journal of the American College of Nutrition, 29, 334s-339s. Karin M. 2006. Nuclear factor-κB in cancer development andprogression. Nature, 441, 431-436. Kerekes G, Szekanecz Z, Dér H, Sandor Z, Lakos G, Muszbek L, Csipó I, Sipka S, Seres I, Paragh G, et al. 2008. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. The Journal of Rheumatology, 35, 398-406. Kishimoto T. 2010. IL-6: from its discovery to clinical applications. International Immunology, 22, 347-352. Kishimoto T, Ishizaka K. 1971. Regulation of antibody response in vitro. Suppression of secondary response by antiimmunoglobulin heavy chains. The Journal of Immunology, 107, 1567-1570. O’Sullivan B, Thompson A, Thomas R. 2007. NF-κB as a therapeutic target in autoimmune disease. Expert Opinion on Therapeutic Targets, 11, 111-122. Pahl H L. 1999. Activators and target genes of Rel’NF-κB transcription factors. Oncogene, 18, 6853-6866. Senftleben U, Karin M. 2002. The IKK/NF-κB pathway. Critical Care Medicine, 30, S105-111. Stankova J, D’Orleans-Juste P, Rola-Pleszczynski M. 1996. ET-1 induces IL-6 gene expression in human umbilical vein endothelial cells: synergistic effect of IL-1. American Journal of Physiology - Cell Physiology, 271, C1073-C1078. Sun D, Lytle C, O´Donnell M E. 1997. IL-6 secreted by astroglial cells regulates Na-K-Cl cotransport in brain microvessel endothelial cells. American Journal of Physiology - Cell Physiology, 272, C1829-C1835. Tabruyn S P, Mémet S, Avé P, Verhaeghe C, Mayo K H, Struman I, Martial J A, Griffioen A W. 2009. NF-κB activation in endothelial cells is critical for the activity of angiostatic agents. Molecular Cancer Therapeutics, 8, 2645-2654. Tak P P, Firestein G S. 2001. NF-κB: a key role in inflammatory disseases. The Journal of Clinical Investigation, 107, 7-11. Wulczyn F G, Krappmann D, Scheidereit C. 1996. The NF-κBRel and IκB gene families: mediators of immune response and inflammation. Journal of Molecular Medicine, 74, 749- 769. Yorek M A, Dunlap J A, Thomas M J, Cammarata P R, Zhou C, Lowe W L. 1998. Effect of TNF-a on SMIT mRNA levels and myo-inositol accumulation in cultured endothelial cells. American Journal of Physiology - Cell Physiology, 274, 58- 71. Zingarelli B, Sheehan M, Wong H R. 1997. Nuclear factor-κB as a therapeutic expression by PPM-18, a novel antiinflammatory agent, in vitro and in vivo. Biochemical Journal, 328, 363-369. |